---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-047567"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T09:38:34.330943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M

## Summary
- Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.
- Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.
- Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.
- Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.
- Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024.

## SEC filing metadata
- accession: 0000950170-24-047567
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/vktx-20240424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-047567
- JSON: https://secwatch.observer/filing/0000950170-24-047567.json
- Plain text: https://secwatch.observer/filing/0000950170-24-047567.txt

## Key facts
- Earnings Releases
  Viking Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.